Putting Long-Term Adverse Events of Bisphosphonates into Perspective

Solomon DH Avorn J Katz JN Compliance with osteoporosis medications. Arch Intern Med 2005; 165 (20): 2414–9.

McHorney CA Schousboe JT Cline RR Weiss TW . The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 2007; 23 (12): 3137–52.

Papaioannou A Morin S Cheung AM 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182: 1864–73.

Bone HG Hosking D Devogelaer JP Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189–99.

Mellström DD Sörenson OH Goemaere S Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 462–8.

American Association of Oral and Maxillofacial Surgeons: position paper on bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 2007; 3: 369–76.

Khosla S Burr D Cauley J Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society of Bone and Mineral Research. J Bone Miner Res 2008; 23: 826–36.

Solomon DH Rekedal L Cadarette SM . Osteoporosis treatment and adverse events. Curr Opin Rheumatol 2009; 21: 363–8.

Watts NB Diab DL . Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010; 95 (4): 1555–65.

Black DM Delmas PD Eastell R HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of osteoporosis. N Engl J Med 2007; 356: 1809–22.

US Food and Drug Administration. FDA Alert: information for healthcare professionals: bisphosphonates. Available: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124165.htm (accessed Feb. 23, 2011).

Abrahamsen B . Adverse effects of bisphosphonates. Calcif Tissue Int 2010; 86: 421–35.

Shane E Burr D Ebeling PR Abrahamsen B Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010:25 (11): 2267–94.

Odvina CV Zerwekh JE Rao DS Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294–301.

Black DM Cummings SR Karpf Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–41.

Harris ST Watts NB Genant HK Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282: 1344–52.